La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Xvivo Perfusion Crescita futura

Future criteri di controllo 5/6

Xvivo Perfusion prevede che gli utili e i ricavi cresceranno rispettivamente di 36.9% e 26.7% all'anno. Si prevede che l'EPS crescerà di 41.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 10.5% in 3 anni.

Informazioni chiave

36.9%

Tasso di crescita degli utili

41.6%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	25.5%
Tasso di crescita dei ricavi	26.7%
Rendimento futuro del capitale proprio	10.5%
Copertura analitica	Good
Ultimo aggiornamento	19 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Aug 03

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Apr 25

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Apr 11

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

Feb 05

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Feb 01

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jan 28

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Nov 17

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively

Aug 20

Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are

Jul 21

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

Mar 30

At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?

Feb 18

A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)

Jan 30

Previsioni di crescita degli utili e dei ricavi

OM:XVIVO - Stime future degli analisti e dati finanziari passati (SEK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	1,543	301	151	408	4
12/31/2025	1,131	178	4	248	6
12/31/2024	844	96	-39	176	6
6/30/2024	699	121	-103	69	N/A
3/31/2024	643	100	-93	60	N/A
12/31/2023	598	92	-98	46	N/A
9/30/2023	573	24	-72	50	N/A
6/30/2023	524	27	-86	42	N/A
3/31/2023	463	28	-108	25	N/A
12/31/2022	415	18	-103	28	N/A
9/30/2022	370	30	-127	6	N/A
6/30/2022	328	23	-138	-20	N/A
3/31/2022	293	7	-138	-32	N/A
12/31/2021	258	8	-106	-12	N/A
9/30/2021	233	-24	-116	-33	N/A
6/30/2021	221	-37	-104	-27	N/A
3/31/2021	192	-44	-79	-11	N/A
12/31/2020	180	-44	-77	-12	N/A
9/30/2020	182	-26	-68	3	N/A
6/30/2020	194	-6	-54	20	N/A
3/31/2020	220	12	-49	39	N/A
12/31/2019	221	5	-54	30	N/A
9/30/2019	217	12	-37	34	N/A
6/30/2019	203	7	-42	23	N/A
3/31/2019	193	9	-41	15	N/A
12/31/2018	188	13	-31	24	N/A
9/30/2018	171	13	-21	34	N/A
6/30/2018	162	13	-14	38	N/A
3/31/2018	153	10	N/A	33	N/A
12/31/2017	148	6	N/A	22	N/A
9/30/2017	145	0	N/A	8	N/A
6/30/2017	145	0	N/A	6	N/A
3/31/2017	142	0	N/A	5	N/A
12/31/2016	138	2	N/A	13	N/A
9/30/2016	132	5	N/A	22	N/A
6/30/2016	127	7	N/A	19	N/A
3/31/2016	122	6	N/A	20	N/A
12/31/2015	120	5	N/A	9	N/A
9/30/2015	113	4	N/A	-1	N/A
6/30/2015	109	4	N/A	1	N/A
3/31/2015	98	3	N/A	-7	N/A
12/31/2014	85	5	N/A	-5	N/A
9/30/2014	79	6	N/A	9	N/A
6/30/2014	74	7	N/A	3	N/A
3/31/2014	71	7	N/A	6	N/A
12/31/2013	69	8	N/A	13	N/A
9/30/2013	64	5	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di XVIVO ( 36.9% all'anno) è superiore al tasso di risparmio ( 1.1% ).

Guadagni vs Mercato: Si prevede che gli utili di XVIVO ( 36.9% all'anno) cresceranno più rapidamente del mercato Swedish ( 16% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di XVIVO cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di XVIVO ( 26.7% all'anno) crescerà più rapidamente del mercato Swedish ( 1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di XVIVO ( 26.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di XVIVO sarà basso tra 3 anni ( 10.5 %).

Xvivo Perfusion Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 27%

Consensus EPS estimates increase by 16%

Recent updates

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?

Consensus EPS estimates increase by 19%

Price target increased by 16% to kr509

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target increased by 8.1% to kr450

Consensus EPS estimates increase by 10%

Now 20% undervalued

Independent Director recently bought kr222k worth of stock

Consensus EPS estimates increase by 27%

Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague

Consensus EPS estimates increase by 16%

There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital

Consensus EPS estimates increase by 17%, revenue downgraded

Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates

We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings

Chairman of the Board recently bought kr281k worth of stock

Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter 2023 earnings released: EPS: kr0.076 (vs kr0.18 in 3Q 2022)

Xvivo Perfusion AB (publ) to Report First Half, 2024 Results on Jul 12, 2024

Price target increased by 7.9% to kr407

Consensus EPS estimates fall by 13%

Price target increased by 8.0% to kr407

Chairman of the Board recently bought kr125k worth of stock

Xvivo Perfusion AB (publ) Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published

Consensus EPS estimates fall by 24%

Xvivo Perfusion AB (publ) Announces Leading Acacemic Medical Center Performs First Heart Transplant in the U.S. Utilizing NIHP Technology as Part of Xvivo's Preserve Clinical Trial

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2024

Now 24% undervalued

New minor risk - Shareholder dilution

Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled

Consensus EPS estimates increase by 42%

US Food & Drug Administration Grants Xvivo Perfusion AB (publ) Approval to Include DCD Heartarts in IDE Clinical Trial

Consensus EPS estimates fall by 33%

Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces Its Decision to Close the PrimECC(R) Study for Further Patient Inclusions - Strategic Opportunities Will Be Evaluated

Consensus EPS estimates fall by 12%

Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?

Xvivo Announces Patient Inclusion Completed in European Clinical Trial with Heart Preservation Technology

Consensus revenue estimates increase by 10%

Independent Director recently bought kr107k worth of stock

Consensus EPS estimates fall by 30%

Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital

Now 22% undervalued

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued

Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?

With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case

When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?

Now 21% undervalued

Full year 2022 earnings released: EPS: kr0.62 (vs kr0.28 in FY 2021)

Xvivo Perfusion AB (publ), Annual General Meeting, Apr 25, 2023

Consensus EPS estimates fall by 12%

Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital

XVIVO Perfusion AB (Publ) Appoints Christoffer Rosenblad as CEO

XXvivo Perfusion AB (publ) Appoints Lena Hagman to Chief Operating Officer, COO

Consensus EPS estimates increase by 14%

Xvivo Perfusion AB (Publ) Presents Positive Results from the Australian & New Zealand Heart Preservation Study

Consensus EPS estimates increase by 14%

Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?

Chairman of the Board recently bought kr201k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xvivo Perfusion AB (publ) Announces CEO Changes

XVIVO Perfusion AB Receives Breakthrough Device Designation Grant from the FDA for the Liver Assist Device

Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively